Nada Jabado

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8370994/publications.pdf

Version: 2024-02-01

239 papers	34,779 citations	4641 85 h-index	3815 178 g-index
248 all docs	248 docs citations	248 times ranked	31204 citing authors

#	Article	IF	Citations
1	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	13.7	2,129
2	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
3	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	7.7	1,551
4	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	7.7	836
5	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica, 2012, 124, 439-447.	3.9	799
6	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	13.7	787
7	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	13.7	765
8	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	13.7	761
9	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. Cell, 2012, 148, 59-71.	13.5	743
10	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 32, 520-537.e5.	7.7	716
11	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
12	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. Journal of Clinical Oncology, 2016, 34, 2206-2211.	0.8	692
13	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	9.4	674
14	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	7.7	633
15	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	7.7	627
16	Phosphoinositide 3-Kinase Î´ Gene Mutation Predisposes to Respiratory Infection and Airway Damage. Science, 2013, 342, 866-871.	6.0	541
17	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature, 2014, 506, 445-450.	13.7	521
18	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 2014, 14, 92-107.	12.8	469

#	Article	IF	Citations
19	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	7.7	438
20	Griscelli disease maps to chromosome 15q21 and is associated with mutations in the Myosin-Va gene. Nature Genetics, 1997, 16, 289-292.	9.4	419
21	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	0.8	381
22	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 2014, 46, 462-466.	9.4	381
23	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathologica, 2012, 124, 615-625.	3.9	376
24	Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature, 2012, 482, 529-533.	13.7	376
25	Natural Resistance to Intracellular Infections. Journal of Experimental Medicine, 2000, 192, 1237-1248.	4.2	354
26	The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape. Nature, 2019, 573, 281-286.	13.7	338
27	Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science, 2016, 352, 844-849.	6.0	327
28	Utility of wholeâ€exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care. Clinical Genetics, 2016, 89, 275-284.	1.0	323
29	What can exome sequencing do for you?. Journal of Medical Genetics, 2011, 48, 580-589.	1.5	321
30	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	5.1	307
31	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature, 2019, 572, 67-73.	13.7	293
32	Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. Journal of Pediatrics, 1999, 134, 589-596.	0.9	282
33	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678.	3.9	277
34	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	5.1	274
35	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	5.1	268
36	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	13.7	266

#	Article	IF	Citations
37	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	0.8	263
38	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathologica, 2013, 125, 659-669.	3.9	250
39	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	0.8	250
40	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	0.8	232
41	Frequency and Severity of Central Nervous System Lesions in Hemophagocytic Lymphohistiocytosis. Blood, 1997, 89, 794-800.	0.6	225
42	BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma. Clinical Cancer Research, 2011, 17, 4790-4798.	3.2	219
43	Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-Oncology, 2017, 19, now101.	0.6	217
44	H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis. Nature Communications, 2019, 10, 1262.	5.8	215
45	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	9.4	214
46	Oncogenic FAM131Bâ€“BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathologica, 2011, 121, 763-774.	3.9	211
47	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 2016, 7, 11185.	5.8	197
48	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathologica, 2011, 122, 231-240.	3.9	195
49	Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas. Nature Genetics, 2017, 49, 180-185.	9.4	195
50	H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. Cancer Cell, 2017, 32, 684-700.e9.	7.7	192
51	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	7.7	191
52	Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors. Journal of Clinical Oncology, 2007, 25, 1196-1208.	0.8	187
53	Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience. European Journal of Cancer, 2012, 48, 353-359.	1.3	186
54	CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature, 2014, 510, 288-292.	13.7	174

#	Article	IF	Citations
55	Nramp 2 (DCT1/DMT1) Expressed at the Plasma Membrane Transports Iron and Other Divalent Cations into a Calcein-accessible Cytoplasmic Pool. Journal of Biological Chemistry, 2000, 275, 35738-35745.	1.6	173
56	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature, 2018, 553, 101-105.	13.7	170
57	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathologica, 2017, 134, 705-714.	3.9	168
58	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nature Genetics, 2014, 46, 39-44.	9.4	167
59	Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. British Journal of Cancer, 2009, 101, 722-733.	2.9	163
60	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	0.8	160
61	Phase II Weekly Vinblastine for Chemotherapy-NaÃ¯ve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology, 2016, 34, 3537-3543.	0.8	157
62	Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nature Genetics, 2018, 50, 1650-1657.	9.4	151
63	Human RTEL1 deficiency causes Hoyeraalâ€“Hreidarsson syndrome with short telomeres and genome instability. Human Molecular Genetics, 2013, 22, 3239-3249.	1.4	150
64	Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma. Cancer Research, 2010, 70, 2548-2557.	0.4	149
65	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncology, The, 2015, 16, 569-582.	5.1	147
66	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	3.9	146
67	Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathologica, 2016, 131, 847-863.	3.9	143
68	Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. Cancer Cell, 2019, 35, 782-797.e8.	7.7	143
69	PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. Nature Communications, 2019, 10, 2146.	5.8	136
70	Stalled developmental programs at the root of pediatric brain tumors. Nature Genetics, 2019, 51, 1702-1713.	9.4	136
71	Invasive Pulmonary Infection Due toScedosporium apiospermumin Two Children with Chronic Granulomatous Disease. Clinical Infectious Diseases, 1998, 27, 1437-1441.	2.9	135
72	Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas. Clinical Cancer Research, 2011, 17, 4650-4660.	3.2	135

#	Article	IF	Citations
73	A Recurrent PDGFRB Mutation Causes Familial Infantile Myofibromatosis. American Journal of Human Genetics, 2013, 92, 996-1000.	2.6	135
74	Linkage of Familial Hemophagocytic Lymphohistiocytosis to 10q21-22 and Evidence for Heterogeneity. American Journal of Human Genetics, 1999, 64, 172-179.	2.6	133
75	Recurrent noncoding U1ÂsnRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature, 2019, 574, 707-711.	13.7	129
76	Whole-exome sequencing identifies Coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation. Journal of Allergy and Clinical Immunology, 2013, 131, 1594-1603.e9.	1.5	127
77	A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro-Oncology, 2013, 15, 462-468.	0.6	119
78	Unexpected allelic heterogeneity and spectrum of mutations in Fowler syndrome revealed by next-generation exome sequencing. Human Mutation, 2010, 31, 918-923.	1.1	116
79	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathologica, 2014, 128, 733-741.	3.9	116
80	Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology, 2018, 20, 160-173.	0.6	116
81	Treatment of Familial Hemophagocytic Lymphohistiocytosis With Bone Marrow Transplantation From HLA Genetically Nonidentical Donors. Blood, 1997, 90, 4743-4748.	0.6	112
82	Spatial heterogeneity in medulloblastoma. Nature Genetics, 2017, 49, 780-788.	9.4	112
83	FOXP3 Forkhead Domain Mutation and Regulatory T Cells in the IPEX Syndrome. New England Journal of Medicine, 2009, 361, 1710-1713.	13.9	105
84	New technologies for the detection of circulating tumour cells. British Medical Bulletin, 2010, 94, 49-64.	2.7	103
85	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	13.7	94
86	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer, 2019, 19, 1250.	1.1	93
87	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell, 2020, 183, 1617-1633.e22.	13.5	93
88	Diffuse intrinsic pontine gliomasâ€"current management and new biologic insights. Is there a glimmer of hope?. Neuro-Oncology, 2017, 19, 1025-1034.	0.6	91
89	Circulating tumor cells: detection, molecular profiling and future prospects. Expert Review of Proteomics, 2007, 4, 741-756.	1.3	90
90	Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3544-3549.	3.3	90

#	Article	IF	Citations
91	MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell, 2015, 28, 715-729.	7.7	90
92	A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. Human Molecular Genetics, 2000, 9, 583-588.	1.4	85
93	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. Cell, 2018, 172, 1050-1062.e14.	13.5	85
94	Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. Acta Neuropathologica, 2013, 126, 291-301.	3.9	84
95	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	3.2	84
96	H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2. Molecular Cell, 2020, 80, 726-735.e7.	4.5	83
97	Attitudes of parents toward the return of targeted and incidental genomic research findings in children. Genetics in Medicine, 2014, 16, 633-640.	1.1	82
98	Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. Cell, 2020, 181, 1329-1345.e24.	13.5	79
99	Severe combined immunodeficiency caused by deficiency in either the Î´ or the Îµ subunit of CD3. Journal of Clinical Investigation, 2004, 114, 1512-1517.	3.9	78
100	Trametinib for progressive pediatric low-grade gliomas. Journal of Neuro-Oncology, 2018, 140, 435-444.	1.4	75
101	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro-Oncology, 2021, 23, 34-43.	0.6	75
102	Chromatin Remodeling Defects in Pediatric and Young Adult Glioblastoma: A Tale of a Variant <scp>H</scp>istone 3 Tail. Brain Pathology, 2013, 23, 210-216.	2.1	74
103	Nramp1 Modifies the Fusion of Salmonella typhimurium-containing Vacuoles with Cellular Endomembranes in Macrophages. Journal of Biological Chemistry, 2002, 277, 2258-2265.	1.6	73
104	Inhibition of medulloblastoma cell invasion by Slit. Oncogene, 2006, 25, 5103-5112.	2.6	73
105	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	0.6	73
106	Protein truncation test of LYST reveals heterogenous mutations in patients with Chediak-Higashi syndrome. Blood, 2000, 95, 979-83.	0.6	73
107	Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro-Oncology, 2010, 12, 153-163.	0.6	72
108	Barriers to horizontal cell transformation by extracellular vesicles containing oncogenic H-ras. Oncotarget, 2016, 7, 51991-52002.	0.8	72

#	Article	IF	Citations
109	Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas. Nature Communications, 2021, 12, 971.	5.8	71
110	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	7.7	69
111	Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood, 1997, 89, 794-800.	0.6	67
112	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathologica, 2020, 139, 223-241.	3.9	65
113	Interaction of HIV gp120 and anti-CD4 antibodies with the CD4 molecule on human CD4+ T cells inhibits the binding activity of NF-AT, NF-Ï‡B and AP-1, three nuclear factors regulating interleukin-2 gene enhancer activity. European Journal of Immunology, 1994, 24, 2646-2652.	1.6	61
114	Iron transporter Nramp2/DMT-1 is associated with the membrane of phagosomes in macrophages and Sertoli cells. Blood, 2002, 100, 2617-2622.	0.6	61
115	X-linked primary immunodeficiency associated with hemizygous mutations in the moesin (MSN) gene. Journal of Allergy and Clinical Immunology, 2016, 138, 1681-1689.e8.	1.5	60
116	Gene Expression Profiling from Formalin-Fixed Paraffin-Embedded Tumors of Pediatric Glioblastoma. Clinical Cancer Research, 2007, 13, 6284-6292.	3.2	58
117	TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw. Nature Communications, 2018, 9, 4572.	5.8	58
118	Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. British Journal of Haematology, 1998, 103, 543-551.	1.2	57
119	Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27354-27364.	3.3	57
120	Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. European Journal of Immunology, 1997, 27, 2043-2047.	1.6	51
121	Diffuse glioneuronal tumour with oligodendrogliomaâ€like features and nuclear clusters (DGONC) â€“ a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. Neuropathology and Applied Neurobiology, 2020, 46, 422-430.	1.8	51
122	H3K27M in Gliomas Causes a One-Step Decrease in H3K27 Methylation and Reduced Spreading within the Constraints of H3K36 Methylation. Cell Reports, 2020, 33, 108390.	2.9	50
123	Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Molecular Cancer Therapeutics, 2009, 8, 3276-3284.	1.9	49
124	Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. Acta Neuropathologica, 2014, 128, 615-627.	3.9	49
125	Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. Acta Neuropathologica Communications, 2017, 5, 78.	2.4	48
126	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	5.8	47

#	Article	IF	Citations
127	Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathologica, 2014, 128, 853-862.	3.9	46
128	Preclinical target validation using patient-derived cells. Nature Reviews Drug Discovery, 2015, 14, 149-150.	21.5	46
129	ZFTAâ€“RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. Cancer Discovery, 2021, 11, 2200-2215.	7.7	46
130	Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Advances, 2021, 5, 1682-1694.	2.5	46
131	Attitudes of Canadian researchers toward the return to participants of incidental and targeted genomic findings obtained in a pediatric research setting. Genetics in Medicine, 2013, 15, 558-564.	1.1	45
132	YAP1-fusions in pediatric NF2-wildtype meningioma. Acta Neuropathologica, 2020, 139, 215-218.	3.9	45
133	CD4 ligands inhibit the formation of multifunctional transduction complexes involved in T cell activation. Journal of Immunology, 1997, 158, 94-103.	0.4	45
134	Iron chelators modulate the fusogenic properties of Salmonella-containing phagosomes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6127-6132.	3.3	44
135	Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. Journal of Neuro-Oncology, 2017, 132, 155-162.	1.4	43
136	Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteria. Histopathology, 2001, 38, 146-159.	1.6	42
137	White matter and information processing speed following treatment with cranial-spinal radiation for pediatric brain tumor.. Neuropsychology, 2016, 30, 425-438.	1.0	42
138	Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor. Oncotarget, 2016, 7, 1732-1740.	0.8	42
139	Impact of HLA matching on outcome of hematopoietic stem cell transplantation in children with inherited diseases: a single-center comparative analysis of genoidentical, haploidentical or unrelated donors. Bone Marrow Transplantation, 2004, 33, 1089-1095.	1.3	41
140	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clinical Cancer Research, 2015, 21, 3750-3758.	3.2	40
141	H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone. Cancer Discovery, 2020, 10, 1968-1987.	7.7	40
142	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	0.8	40
143	Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma. Acta Neuropathologica, 2011, 121, 229-239.	3.9	39
144	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. Cell Reports, 2020, 33, 108286.	2.9	39

#	Article	IF	Citations
145	An inherited immunoglobulin class-switch recombination deficiency associated with a defect in the INO80 chromatin remodeling complex. Journal of Allergy and Clinical Immunology, 2015, 135, 998-1007.e6.	1.5	37
146	Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness. Nature Communications, 2019, 10, 2891.	5.8	36
147	Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers. JAMA Network Open, 2019, 2, e192906.	2.8	36
148	Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. Pediatrics, 1996, 98, 420-8.	1.0	34
149	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	3.9	33
150	Long-term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiency. Pediatric Transplantation, 2007, 11, 209-213.	0.5	32
151	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells. American Journal of Pathology, 2016, 186, 446-459.	1.9	32
152	gp160 of HIV or anti-CD4 monoclonal antibody ligation of CD4 induces inhibition of JNK and ERK-2 activities in human peripheral CD4+ T lymphocytes. European Journal of Immunology, 1997, 27, 397-404.	1.6	31
153	Isolation of a Natural Inhibitor of Human Malignant Glial Cell Invasion: Inter Î±-Trypsin Inhibitor Heavy Chain 2. Cancer Research, 2006, 66, 1464-1472.	0.4	30
154	EZH2 expression is a prognostic factor in childhood intracranial ependymoma: A Canadian Pediatric Brain Tumor Consortium study. Cancer, 2015, 121, 1499-1507.	2.0	30
155	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. Current Oncology, 2021, 28, 346-366.	0.9	27
156	Sam68 association with p120GAP in CD4+ T cells is dependent on CD4 molecule expression. Journal of Immunology, 1998, 161, 2798-803.	0.4	27
157	Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours. Proteomics, 2013, 13, 1595-1607.	1.3	26
158	Histone H3.3 K27M and K36M mutations de-repress transposable elements through perturbation of antagonistic chromatin marks. Molecular Cell, 2021, 81, 4876-4890.e7.	4.5	26
159	Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. Pediatric Blood and Cancer, 2018, 65, e27389.	0.8	25
160	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. Clinical Cancer Research, 2018, 24, 1355-1363.	3.2	24
161	Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. Genome Medicine, 2013, 5, 66.	3.6	23
162	Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors. Blood, 1997, 90, 4743-8.	0.6	23

#	Article	IF	Citations
163	The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas. Annual Review of Genetics, 2019, 53, 483-503.	3.2	22
164	Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA Oncology, 2021, 7, 1806.	3.4	22
165	Ligands of CD4 inhibit the association of phospholipase CÎ³1 with phosphoinositide 3 kinase in T cells: regulation of this association by the phosphoinositide 3 kinase activity. European Journal of Immunology, 1998, 28, 3183-3191.	1.6	21
166	Reduced in vitro functional activity of human NRAMP1 (SLC11A1) allele that predisposes to increased risk of pediatric tuberculosis disease. Genes and Immunity, 2007, 8, 691-698.	2.2	21
167	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. Clinical Epigenetics, 2019, 11, 117.	1.8	21
168	Brainstem angiocentric gliomas with MYBâ€“QKI rearrangements. Acta Neuropathologica, 2017, 134, 667-669.	3.9	20
169	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. European Journal of Cancer, 2020, 139, 135-148.	1.3	20
170	Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nature Cancer, 2022, 3, 994-1011.	5.7	20
171	Iron Refractory Iron Deficiency Anemia: Presentation With Hyperferritinemia and Response to Oral Iron Therapy. Pediatrics, 2013, 131, e620-e625.	1.0	19
172	The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience. Child's Nervous System, 2015, 31, 57-65.	0.6	19
173	Oncohistones: a roadmap to stalled development. FEBS Journal, 2022, 289, 1315-1328.	2.2	19
174	Methylome analysis and whole-exome sequencing reveal that brain tumors associated with encephalocraniocutaneous lipomatosis are midline pilocytic astrocytomas. Acta Neuropathologica, 2018, 136, 657-660.	3.9	18
175	Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas. Science Translational Medicine, 2021, 13, eabf7860.	5.8	18
176	Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine. Child's Nervous System, 2009, 25, 39-45.	0.6	17
177	Polycomb repressive complex 2 in the driverâ€™s seat of childhood and young adult brain tumours. Trends in Cell Biology, 2021, 31, 814-828.	3.6	17
178	Intestinal Neoplasia Induced by Low Dietary Folate Is Associated with Altered Tumor Expression Profiles and Decreased Apoptosis in Mouse Normal Intestine. Journal of Nutrition, 2009, 139, 488-494.	1.3	16
179	Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. Nature Cancer, 2022, 3, 629-648.	5.7	16
180	Changes in the expression profiles of claudins during gonocyte differentiation and in seminomas. Andrology, 2016, 4, 95-110.	1.9	15

#	Article	IF	Citations
181	Molecular biomarkers in pediatric glial tumors. Current Opinion in Oncology, 2013, 25, 665-673.	1.1	14
182	Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. Oncotarget, 2015, 6, 31844-31856.	0.8	14
183	Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma. Oncogene, 2019, 38, 2994-3002.	2.6	13
184	Canadian Pediatric Neuro-Oncology Standards of Practice. Frontiers in Oncology, 2020, 10, 593192.	1.3	13
185	Promoting an ethic of engagement in pediatric palliative care research. BMC Palliative Care, 2015, 14, 50.	0.8	12
186	Entering the era of precision medicine in pediatric oncology. Nature Medicine, 2020, 26, 1684-1685.	15.2	12
187	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	2.7	12
188	Stem cell transplantation for immunodeficiency. Seminars in Immunopathology, 1998, 19, 479-492.	4.0	11
189	Complete DiGeorge Anomaly in the Absence of Neonatal Hypocalcemia and Velofacial and Cardiac Defects. Pediatrics, 2005, 116, e457-e460.	1.0	11
190	Primary Hyperparathyroidism Mimicking Vaso-occlusive Crises in Sickle Cell Disease. Pediatrics, 2006, 118, e537-e539.	1.0	11
191	In VivoInfusion of Anti-LFA-1 and Anti-CD2 Antibodies Prevents Graft Failure After HLA Partially Incompatible Bone Marrow Transplantation in Children with High Risk Acute Lymphoblastic Leukaemia. Leukemia and Lymphoma, 1997, 28, 103-112.	0.6	9
192	Biomarkers in cancer micrometastasis: where are we at?. Bioanalysis, 2010, 2, 881-899.	0.6	9
193	Recurrent inflammatory disease caused by a heterozygous mutation in CD48. Journal of Allergy and Clinical Immunology, 2019, 144, 1441-1445.e17.	1.5	9
194	Epigenomic programming in early fetal brain development. Epigenomics, 2020, 12, 1053-1070.	1.0	9
195	The protein tyrosine kinase p60c-Src is not implicated in the pathogenesis of the human autosomal recessive form of osteopetrosis: A study of 13 children. Journal of Pediatrics, 1998, 133, 537-543.	0.9	8
196	The genetics of vulnerability. Nature, 2005, 434, 709-711.	13.7	8
197	PAX3is Expressed in the Stromal Compartment of the Developing Kidney and in Wilms Tumors with Myogenic Phenotype. Pediatric and Developmental Pathology, 2009, 12, 347-354.	0.5	8
198	Pachyonychia Congenita (K16) with Unusual Features and Good Response to Acitretin. Case Reports in Dermatology, 2015, 7, 220-226.	0.3	8

#	Article	IF	Citations
199	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). Journal of Neuro-Oncology, 2020, 149, 45-54.	1.4	8
200	Relative CD4 lymphopenia and a skewed memory phenotype are the main immunologic abnormalities in a child with Omenn syndrome due to homozygous RAG1-C2633T hypomorphic mutation. Clinical Immunology, 2009, 131, 447-455.	1.4	7
201	H3.1 K36M mutation in a congenitalâ€onset soft tissue neoplasm. Pediatric Blood and Cancer, 2017, 64, e26633.	0.8	7
202	Differential CD4-dependent inhibition of JNK but not Erk-2 activities in human naive and memory CD4+ T cell populations. International Immunology, 1998, 10, 869-876.	1.8	6
203	Pediatric Hemophagocytic Syndromes: A Diagnostic and Therapeutic Challenge. Allergy, Asthma and Clinical Immunology, 2005, 1, 142.	0.9	6
204	De novo TRPV4 Leu619Pro variant causes a new channelopathy characterised by giant cell lesions of the jaws and skull, skeletal abnormalities and polyneuropathy. Journal of Medical Genetics, 2022, 59, 305-312.	1.5	6
205	Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors. Acta Neuropathologica, 2021, 142, 361-374.	3.9	6
206	Atypical presentation of acute promyelocytic leukaemia. British Journal of Haematology, 2006, 132, 379-380.	1.2	5
207	Identification of genes functionally involved in the detrimental effects of mutant histone H3.3-K27M in Drosophila melanogaster. Neuro-Oncology, 2019, 21, 628-639.	0.6	5
208	An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. Acta Neuropathologica, 2020, 140, 237-239.	3.9	5
209	Incidence trends in pediatric central nervous system tumors in Canada: a 15 years report from Cancer and Young People in Canada (CYP-C) registry. Neuro-Oncology Advances, 2020, 2, vdaa012.	0.4	5
210	Wholeâ€exome sequencing reveals novel vacuolar ATPase genesâ€™ variants and variants in genes involved in lysosomal biology and autophagosomal formation in oral granular cell tumors. Journal of Oral Pathology and Medicine, 2021, 50, 410-417.	1.4	5
211	Pediatric Brain Tumors: Genomics and Epigenomics Pave the Way. Critical Reviews in Oncogenesis, 2015, 20, 271-299.	0.2	5
212	Murine diet/tissue and human brain tumorigenesis alter Mthfr/MTHFR 5â€²-end methylation. Mammalian Genome, 2016, 27, 122-134.	1.0	4
213	Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma. Pediatric Blood and Cancer, 2017, 64, 275-278.	0.8	4
214	Fibrinogen Montreal: a novel missense mutation (Aa D496N) associated with hypofibrinogenaemia. Thrombosis and Haemostasis, 2006, 96, 231-2.	1.8	4
215	FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS10062-TPS10062.	0.8	4
216	Wilms tumor arising in a child with X-linked nephrogenic diabetes insipidus. Pediatric Nephrology, 2009, 24, 1313-1319.	0.9	3

#	Article	IF	Citations
217	Drosophila Tet Is Required for Maintaining Glial Homeostasis in Developing and Adult Fly Brains. ENeuro, 2022, 9, ENEURO.0418-21.2022.	0.9	3
218	Integrative Genomic Analyses of Atypical Teratoid Rhabdoid Tumours (ATRTs). Cancer Genetics, 2014, 207, 447-448.	0.2	2
219	Reduced recruitment of 53BP1 during interstrand crosslink repair is associated with genetically inherited attenuation of mitomycin C sensitivity in a family with Fanconi anemia. Oncotarget, 2018, 9, 3779-3793.	0.8	2
220	Kabuki syndrome stem cell models reveal locus specificity of histone methyltransferase 2D (KMT2D/MLL4). Human Molecular Genetics, 2022, 31, 3715-3728.	1.4	2
221	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway.. Journal of Clinical Oncology, 2022, 40, 2042-2042.	0.8	2
222	Acquired Omenn-Like Syndrome, a Novel Posttransplant Autoaggression Syndrome Reversed by Rapamycin. Vaccine Journal, 2012, 19, 109-112.	3.2	1
223	PDTM-21. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, vi208-vi208.	0.6	1
224	Successful treatment of non-midline primary malignant germ cell tumors with yolk sac components in neonates: report of 2 cases. Journal of Neurosurgery: Pediatrics, 2021, 27, 47-51.	0.8	1
225	LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. Neuro-Oncology, 2020, 22, iii371-iii371.	0.6	1
226	Management of Inoperable Supra-Sellar Low-Grade Glioma With BRAF Mutation in Young Children. Cureus, 2021, 13, e19400.	0.2	1
227	CTNI-06. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. Neuro-Oncology, 2021, 23, vi59-vi60.	0.6	1
228	Mutations in Human Histone H3 are Pre-Leukemic Events and Promote Hematopoietic Stem Cell Expansion and Leukemic Aggressiveness. Experimental Hematology, 2018, 64, S55-S56.	0.2	0
229	Attitudes of Researchers to the Return of Incidental and Targeted Genomic Findings Obtained in a Research Setting to Participants. Blood, 2012, 120, 2069-2069.	0.6	0
230	Single Cell Transcriptomic Analysis of the Histone H3 K27M Mutation in Pre-Leukemic Hematopoietic Stem Cells. Blood, 2019, 134, 3773-3773.	0.6	0
231	ETMR-17. SINGLE-CELL TRANSCRIPTOME ANALYSIS OF ETMR PATIENT SAMPLES. Neuro-Oncology, 2020, 22, iii326-iii326.	0.6	0
232	LGG-35. FUNCTIONAL GENOMIC APPROACHES TO IDENTIFY THERAPEUTIC TARGETS IN MYB AND MYBL1 EXPRESSING PEDIATRIC LOW-GRADE GLIOMAS. Neuro-Oncology, 2020, 22, iii373-iii373.	0.6	0
233	EPCO-06. AGE- AND REGION-SPECIFIC MULTI-OMIC CHARACTERIZATION OF H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 2021, 23, vi2-vi2.	0.6	0
234	DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma. Neuro-Oncology, 2022, 24, i21-i21.	0.6	0

#	Article	IF	Citations
235	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. Neuro-Oncology, 2022, 24, i61-i62.	0.6	0
236	HGG-36. Elucidating the role of long non-coding RNAs in pediatric high grade gliomas. Neuro-Oncology, 2022, 24, i68-i69.	0.6	0
237	LGG-26. Predicting MAPK inhibitor sensitivity in pediatric low-grade gliomas with novel gene expression-derived signatures. Neuro-Oncology, 2022, 24, i93-i94.	0.6	0
238	LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology. Neuro-Oncology, 2022, 24, i101-i102.	0.6	0
239	DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers. Neuro-Oncology, 2022, 24, i21-i22.	0.6	0